A kind of poly-lactide-co-glycolic acid (PLGA) nanoparticles have been designed by loading with Aβ generation inhibitor S1 (PQVGHL peptide) and curcumin to target the detrimental factors in AD development and by conjugating with brain targeting peptide CRT (cyclic CRTIGPSVC peptide), an iron-mimic peptide that targets transferrin receptor (TfR), to improve BBB penetration. The gene discussed is TFRC; the disease is Alzheimer disease.